The U.K.'s cost effectiveness gatekeepers are giving their final blessing to a slew of rheumatoid arthritis biologics--but only for patients with advanced forms of the disease. And drugmakers aren't exactly happy about it.
In designing the operation, it had always intended on expanding there, adding one of the biologic products that are becoming more important to its future.
It's been a long time coming, but Bristol-Myers Squibb's ($BMY) Orencia finally won a new thumbs up from U.K. cost-effectiveness watchdogs. The difference: A new discount, size unspecified, that put the rheumatoid arthritis drug more in line with its peers.
Five years in the making and a year in testing, Bristol-Myers Squibb ($BMY) has now been given the go-ahead by the FDA to begin manufacturing at a new plant in Devens, MA.
Britain's healthcare cost watchdog NICE has recommended against using Bristol-Myers Squibb's (BMY.N) rheumatoid arthritis drug Orencia on the state health service as a second-line treatment. Report
In yet another crackdown on manufacturing violations, the FDA has cited Bristol-Myers Squibb for repeated problems at a plant in Puerto Rico. The plant makes at least eight products, including
Could a label change help Bristol-Myers Squibb give a big boost to arthritis remedy Orencia? The company hopes so. The drug's label had specified Orencia use for patients who didn't respond to
A triad of Bristol-Myers Squibb news today, some good, some not-so-good. First, let's get the earnings out of the way: The company reported a decline in earnings on restructuring charges, but
Four companies, two disputed patents, two multimillion-dollar settlements. Repligen and Bristol-Myers Squibb buried the hatchet over Orencia, the rheumatoid arthritis treatment that's been subject